A Biotech's Binary Bet Ends Badly: The Need-to-Know This Morning
Zentalis Pharmaceuticals Faces Setback
Zentalis Pharmaceuticals announced that the FDA has put a partial hold on clinical trials for its experimental cancer drug azenosertib. This came after two patients passed away, suspected to be due to "presumed sepsis."
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
